H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) today and set a price target of $11.00. The company’s shares closed last Friday at $5.55.
Burns covers the Healthcare sector, focusing on stocks such as Replimune Group, BioNTech SE, and GT Biopharma. According to TipRanks, Burns has an average return of -30.7% and a 19.96% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Y-Mabs Therapeutics with a $11.75 average price target.
See the top stocks recommended by analysts >>
Based on Y-Mabs Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $20.75 million and a GAAP net loss of $6.3 million. In comparison, last year the company earned a revenue of $9.8 million and had a GAAP net loss of $41.13 million
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of YMAB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Read More on YMAB:
